Last updated 2026-09-04
- Went public on NASDAQ (ENLV), Mar 2019
- Raised $100M Follow-on PO, Dec 2022
- Raised $45.9M Follow-on PO, Feb 2021
Total raised
$262.8M
Last: PIPE 2025-11
Stage
Public
Founded
2005
Headcount
34
HQ
Ness Ziona, Israel
Sector
Drug Discovery
About
Enlivex Therapeutics Ltd. is an Israeli clinical-stage macrophage reprogramming immunotherapy company. It focuses on developing Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state for the treatment of inflammatory diseases like osteoarthritis, sepsis, and solid tumors. The company also operates a prediction markets treasury strategy built around the RAIN protocol.
Funding history · 9 rounds · $262.8M total
12 events/rounds · $262.8M Total Funding: $479.8M in Public Equity
Jan 2026
Follow-on PO
$19.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2025
Follow-on PO
$9.3M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2024
Follow-on PO
$5.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Dec 2022
Follow-on PO
$100.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2021
Follow-on PO
$45.9M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Oct 2020
Follow-on PO
$25.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2019
Follow-on PO
$16.8M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2016
Follow-on PO
$6.7M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2014
Follow-on PO
$35.2M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Headcount over time
34 employees (2026-09) · 1 point
Offices
Ness Ziona, Israel · HQ / main office
Q&A
- What is Enlivex Therapeutics' primary focus?
- Enlivex Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory conditions, particularly through macrophage reprogramming. They are also involved in a prediction markets treasury strategy.
- What is Allocetra and what is its purpose?
- Allocetra is Enlivex Therapeutics' universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. It is being developed for the treatment of inflammatory diseases such as osteoarthritis, sepsis, and solid tumors.
- When did Enlivex Therapeutics become a public company?
- Enlivex Therapeutics became public on NASDAQ in March 2019 and on TASE in July 2019.
- What was the most recent funding round for Enlivex Therapeutics?
- Enlivex Therapeutics completed a PIPE funding round in November 2025, raising $212,000,000.
- What was the total amount raised by Enlivex Therapeutics to date?
- According to startupim data, Enlivex Therapeutics has raised a total of $452,200,000 USD.
- What is the current employee count for Enlivex Therapeutics?
- Enlivex Therapeutics currently has 34 employees, falling within the 11-50 employee bucket.
- Has Enlivex Therapeutics received regulatory authorization for clinical trials in knee osteoarthritis?
- Yes, in February 2024, Enlivex Therapeutics received regulatory authorization from Israel’s Health Ministry for the initiation of a Phase 1/2 trial evaluating Allocetra in patients with knee osteoarthritis.
- What is the latest development regarding Allocetra in knee osteoarthritis trials?
- In March 2025, Enlivex announced positive interim data, demonstrating a statistically significant 47.0% durable and persistent pain reduction at six months in patients with moderate to severe knee osteoarthritis.
- Has Enlivex Therapeutics expanded its clinical trials for Allocetra internationally?
- Yes, in January 2023, Enlivex Therapeutics received authorizations from French and Belgian regulatory agencies to expand its Phase II Sepsis clinical trial into France and Belgium.
- What is Enlivex Therapeutics' current market capitalization?
- Enlivex Therapeutics has a market capitalization of $174,225,098 USD.
Team · 13
Shai Novik
Founder · Executive Chairman
Dror Mevorach
Founder · Co-Founder & Scientific Advisor
Oren Hershkovitz
Chief Executive Officer
Einat Galamidi
Chief Medical Officer
Veronique Amor-Baroukh
Chief Operating Officer
Shachar Shlosberger
Chief Financial Officer
Iris Tavor
Senior Director of Quality & Regulatory Affairs
Chen Ankri
Director of Pre-Clinical & Clinical Pharmacology
Sigal Arad
Director of Human Resources
Matteo Renzi
Director
Roger James Pomerantz
Independent Vice Chairman of the Board
Abraham Havron
Independent Director
Gili Hart
Independent Director
Highlights
1 Patents
Tags
cell-therapyinflammatory-diseasescrohn-s-diseasepharmaceuticalscancerimmunologyimmunotherapypharma-companieschronic-patientspatientsautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | enlivex.com |
|---|---|
| linkedin.com/company/19117645 | |
| YouTube | youtube.com/channel/UCGJI8b2YMny7Gxu3mMrQlPg |
Identifiers & details
| Legal name | Enlivex Ltd. |
|---|---|
| Former names | Tolarex |
| Founded | 2005 |
| Employees (exact) | 34 |
| Market cap | $174.2M |
| Status reason | Public on NASDAQ on Mar 2019;Public on TASE on Jul 2019; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Reverse Merger | 2019-03 | NASDAQ | ENLV | |
| Registered Direct Offering | 2024-05 | NASDAQ | ENLV | $5.0M |
| PIPE | 2025-11 | NASDAQ | ENLV | $212.0M |
Radar intelligence
Patents
| EPO | 22 |
|---|
Web history (Wayback)
| Domain | enlivex.com |
|---|
Certificate / subdomain footprint
| Subdomains | 17 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513736264 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2005-09-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — people (1) |
| Registered address | אינשטיין 14 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-30 | עדכון בעלי תפקידים |